Pharming Group NV 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Pharming Group N.V. announced significant revenue increases for fiscal year 2025, driven by strong performance in RUCONEST and Joenja sales.
NASDAQ
Pharming Group N.V. reported significant revenue growth in 2025, driven by strong sales of RUCONEST and Joenja, alongside strategic pipeline advancements and the acquisition of Abliva AB.
NASDAQ
Pharming Group N.V. reports increased revenue driven by RUCONEST sales and highlights strategic pipeline expansion with Joenja and the acquisition of Abliva AB in its 20-F filing.
NASDAQ
Pharming Group N.V. files its 20-F, detailing amended articles of association and financial reporting for the year ended December 31, 2023.